证券代码：688189 证券简称：南新制药 公告编号：2025-029 湖南南新制药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 1、湖南南新制药股份有限公司（以下简称"公司"）股票交易连续三个交易 日内（2025 年 7 月 28 日、7 月 29 日和 7 月 30 日）收盘价格涨幅偏离值累计达 到 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交 易实时监控细则》的有关规定，属于股票交易异常波动的情形。 2、公司近期正在筹划购买某一国内药品技术等资产组事项（以下简称"本 次交易"），尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签 署任何有关收购的意向协议，是否能够顺利实施存在重大不确定性。公司将根据 该事项的进展情况及时履行信息披露义务，具体内容以公司后续公告为准。敬请 广大投资者理性投资，注意风险。 （一）生产经营情况 3、经公司自查，并向控股股东书面发函查证，公司日常经营情况正常，未 发生重大变化，市场环境或行业政策未发生重大 ...

Market Overview - The three major A-share indices showed mixed performance on the morning of the 30th, with the Shanghai Composite Index rising by 0.52%, while the Shenzhen Component Index and the ChiNext Index fell by 0.06% and 0.71% respectively [2] - The total trading volume in the Shanghai and Shenzhen markets reached 1,102.2 billion yuan, a decrease of 43.6 billion yuan compared to the previous day [2] Sector Performance - The innovative drug and film industry sectors experienced gains, with stocks such as Nanjing New Pharmaceutical and Happiness Blue Sea hitting the daily limit of 20% [2] - The battery sector faced adjustments, with companies like Xinyu Ren and Zhengye Technology dropping over 5% [2] - The digital currency sector weakened, with Dongxin Peace falling more than 8% [2] - The diversified financial sector also saw fluctuations, with companies like Nanhua Futures and Zhongyou Capital declining over 5% [2]

Group 1 - The core viewpoint of the news is that Nanjing New Pharmaceutical Co., Ltd. (688189) has experienced a significant stock price increase of 17.01%, closing at 11.9 yuan as of July 29, 2025, with a trading volume of 388,700 hands and a transaction amount of 417 million yuan [1] - The company reported a total operating revenue of 40.62 million yuan for Q1 2025, a year-on-year decrease of 70.21%, and a net profit attributable to shareholders of 8.03 million yuan, down 143.66% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 2.250 and a quick ratio of 2.089, while the debt-to-asset ratio stands at 28.21% [1] Group 2 - Nanjing New Pharmaceutical has made investments in 6 companies and participated in 15 bidding projects, indicating active engagement in business expansion [2] - The company holds 3 trademark registrations and 27 patents, showcasing its commitment to intellectual property development [2] - Additionally, the company possesses 11 administrative licenses, reflecting its compliance and operational capabilities [2]

Market Overview - The Shanghai Composite Index closed up 0.33% at 3609.71 points, while the Shenzhen Component Index rose 0.64% to 11289.41 points, and the ChiNext Index increased by 1.86% to 2406.59 points. The total trading volume in the Shanghai and Shenzhen markets reached 182.96 billion yuan, an increase of approximately 63 billion yuan from the previous day [1] Sector Performance - The insurance and banking sectors experienced declines, while the semiconductor sector saw significant gains, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [1] - The steel sector was also active, with Xining Special Steel and Bayi Steel reaching their daily limit up [1] - The innovative drug concept surged, with Sanyuan Gene rising over 20%, and several other pharmaceutical companies hitting their daily limit up [1][4] Innovative Drug Sector - The innovative drug sector saw a broad rally, with notable gains including Sanyuan Gene up over 20%, Ruizhi Medicine hitting the limit up, and WuXi AppTec increasing nearly 8% [4][6] - WuXi AppTec reported a 96.20% year-on-year increase in total profit and a 101.92% increase in net profit attributable to shareholders for the reporting period. The company expects a revenue growth rate adjustment from 10%-15% to 13%-17% for 2025 [6][7] Semiconductor Sector - The semiconductor sector showed strong performance, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [9] - The U.S. government's recent AI Action Plan aims to accelerate the development of the AI industry while imposing stricter export controls on AI computing power and semiconductor manufacturing, which may accelerate domestic self-sufficiency efforts in China [11] Notable Stocks - The stock of Upwind New Materials surged, breaking the 90 yuan mark and reaching a new historical high, with a cumulative increase of over 10 times since July [13] - The company emphasized that its fundamental business has not undergone significant changes, despite the stock price surge [13]

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook for investment opportunities [3]. Core Insights - The new centralized procurement regulations emphasize "stability in clinical use, quality assurance, prevention of collusion, and countering excessive competition," which are expected to promote the long-term healthy development of the industry [2][32]. - The report suggests focusing on recently launched innovative products, high-quality raw material suppliers, and key products that have passed the consistency evaluation for generic drugs [2][32]. Summary by Sections Market Review - The pharmaceutical and biotechnology index increased by 4% this week, outperforming the CSI 300 index by 2.91 percentage points, ranking second in industry performance [11]. - Year-to-date, the pharmaceutical and biotechnology index has risen by 16.59%, also surpassing the CSI 300 index by 13.45 percentage points [11]. - The chemical pharmaceutical sector showed the highest growth this week at 6.86%, while traditional Chinese medicine had the lowest decline at 0.88% [16][18]. Individual Stock Performance - In the A-share market, 397 out of 474 pharmaceutical stocks rose, with the top five performers being: - Borui Pharmaceutical (+42.35%) - Lisheng Pharmaceutical (+41.68%) - Nanxin Pharmaceutical (+34.95%) - Aosai Kang (+32.77%) - Yipin Hong (+32.13%) [22]. - In the Hong Kong market, 96 out of 106 pharmaceutical stocks increased, with the top performers including: - Clover Biopharma-B (+63.79%) - Lepu Biopharma-B (+62.04%) - Deqi Pharmaceutical-B (+47.04%) [25]. Industry News and Policies - The 11th batch of national centralized drug procurement was officially launched, including 55 varieties across various therapeutic areas, focusing on clinical needs and market realities [28]. - The new procurement rules are more refined, requiring production experience and quality control capabilities from manufacturers, which will help ensure drug quality and promote industry standardization [28]. - The establishment of the "Commercial Insurance Innovative Drug Directory" marks a significant step in building a multi-tiered medical security system, providing new economic support for innovative drug development [28]. Key Company Announcements - Heng Rui Pharmaceutical reported positive results from its GLP-1/GIP dual receptor agonist HRS9531 in a Phase III weight loss study, with an average weight reduction of 19.2% in the treatment group [29][31]. - The report highlights various corporate actions, including stock incentive plans and capital increases by several companies, indicating active corporate governance and strategic investments in the sector [36].

Investment Rating - The industry investment rating is "Overweight" indicating a positive outlook for the sector in the next six months [1][29]. Core Insights - The pharmaceutical and biotechnology sector has shown strong performance, with an overall increase of 4.00% in the week from July 14 to July 18, outperforming the CSI 300 index by 2.91 percentage points [3][11]. - Year-to-date, the sector has risen by 16.59%, ranking third among 31 industries, and has outperformed the CSI 300 index by 13.45 percentage points [3][13]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 30.02 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index [3][17]. Market Performance - The pharmaceutical and biotechnology sector's sub-sectors that performed best last week include chemical pharmaceuticals (6.86%), biological products (3.68%), and medical services (3.14%) [3][11]. - A total of 397 stocks (82.88%) in the sector increased in value, while 70 stocks (14.61%) decreased [3][23]. - The top five performing stocks were: - Borui Pharmaceutical (42.35%) - Lisheng Pharmaceutical (41.68%) - Nanxin Pharmaceutical (34.95%) - Aosaikang (32.77%) - Yipinhong (32.13%) [3][24]. Industry News - The 11th batch of national centralized procurement was officially launched on July 15, with 55 drug varieties included, focusing on mature clinical drugs and excluding new drugs from procurement [4][25]. - He Yuan's plant-derived recombinant human serum albumin (HY1001) was approved for domestic marketing on July 18, aimed at treating liver cirrhosis with low albumin levels [4][26]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector remains a strong investment opportunity, particularly in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [5][27]. - Recommended stocks include: - Buy: Betta Pharmaceuticals, Teva Biologicals, Lao Baixing, Huaxia Eye Hospital, Qianhong Pharmaceutical, Baipusais [5][27]. - Focus: Kelun Pharmaceutical, Rongchang Biotechnology, Lizhu Group, Lingrui Pharmaceutical, Kaili Medical, Kangtai Biotechnology [5][27].

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index, with the Shenwan Pharmaceutical and Biological Index rising by 4.00% from July 14 to July 18, 2025, surpassing the CSI 300 by 2.91 percentage points [2][12]. - Year-to-date, the Shenwan Pharmaceutical and Biological Index has increased by 16.59%, outperforming the CSI 300 by 13.45 percentage points, ranking third among 31 Shenwan primary industry indices [2][13]. - As of July 18, 2025, the valuation of the pharmaceutical sector stands at 29.88 times (TTM overall method, excluding negative values), with a premium of 153.54% compared to the CSI 300 [2][17]. Summary by Sections 1. Weekly Market Review - The pharmaceutical sector's performance from July 14 to July 18, 2025, showed a 4.00% increase, ranking second among 31 industry indices [2][12]. - The sector's valuation as of July 18, 2025, is 29.88 times, with a significant premium over the CSI 300 [2][17]. - Top-performing stocks included Borui Pharmaceutical (+42.35%), Lisheng Pharmaceutical (+41.68%), and Nanxin Pharmaceutical (+34.95%) [3][18]. 2. Important Events - On July 15, the National Healthcare Security Administration held a press conference to discuss the optimization of the national drug procurement policy, announcing the selection of 55 drug varieties for the 11th batch of national procurement [4][21]. 3. Industry Perspective - The 11th batch of national procurement will implement a "low-price declaration" system, requiring the lowest-priced selected enterprises to justify their pricing, ensuring it does not fall below cost [5][22]. - The procurement will continue to exclude new drugs and focus on ensuring quality, with enhanced scrutiny on low-priced selected drugs [5][22]. - The overall procurement policy is expected to gradually improve, balancing price reductions with the need to ensure enterprise profits and public healthcare needs [5][22]. - The report expresses optimism about innovative drugs, overseas expansion, and sectors benefiting from procurement reforms, particularly in insulin and orthopedic segments [5][23].

Group 1 - The A-share innovative drug sector continues to show strong performance, with Weikang Pharmaceutical hitting a 20% daily limit increase [1] - Seer Medical also reached its limit, while companies such as Nanjing New Pharmaceutical, Lianhuan Pharmaceutical, Anglikang, and Boji Medical experienced upward trends [1]

Market Overview - A-shares showed mixed performance on July 14, with the Shanghai Composite Index rising by 0.27% to close at 3519.65 points, while the Shenzhen Component Index fell by 0.11% to 10684.52 points, and the ChiNext Index decreased by 0.45% to 2197.07 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 145.88 billion yuan, a decrease of 25.34 billion yuan compared to the previous Friday [1] - Among industry sectors, precious metals, energy metals, electric machinery, plastic products, electric power, paper printing, and power grid equipment saw the highest gains, while diversified finance, gaming, and cultural media sectors experienced the largest declines [1] Lithium Industry - The lithium mining sector showed strong performance on July 14, with institutions noting that industries like polysilicon and lithium carbonate are facing severe internal competition, leading to pressure on both supply and demand [1] - Short-term policies aimed at limiting inefficient capacity expansion may lead to temporary supply tightness, potentially driving prices up, but demand from sectors like new energy vehicles may slow down, limiting price increases [1] Robotics Sector - Robotics stocks collectively surged due to the upcoming 2025 World Artificial Intelligence Conference and the High-Level Meeting on Global Governance of Artificial Intelligence scheduled for July 26-28 in Shanghai, which is expected to positively impact the sector [1] - Robotics and artificial intelligence are identified as one of the more certain investment themes for the year, with potential opportunities in the future [1] Company Specifics - Nanxin Pharmaceutical - Nanxin Pharmaceutical's stock rose by 18.16%, leading the gains among Hunan stocks, with 83 out of 147 stocks in the region showing an increase [2] - The company specializes in the research, production, and sales of pharmaceutical products, primarily focusing on chemical drug formulations for various medical fields [2] - The company's Q1 2025 report indicated a net profit of -8.03 million yuan, with a year-on-year growth rate of -143.66% [2] Company Updates - Nanxin Pharmaceutical - Recent updates from Nanxin Pharmaceutical revealed a significant reduction in production deviation occurrences for 2024 compared to 2023, with a 100% pass rate in external inspections [3] - The company is progressing with its Phase II clinical trial for its innovative drug, Mefenamic Acid, which aims to delay kidney fibrosis and improve kidney function in diabetic nephropathy treatment [3]

Core Viewpoint - On July 14, the Shanghai Composite Index rose by 0.27%, with institutional investors appearing on the trading lists of 35 stocks, net buying 19 and net selling 16 [1] Institutional Trading Summary - Institutional special seats net bought the most in Xiangyang Bearing, which closed at the daily limit with a turnover rate of 27.67% and a transaction amount of 2.076 billion yuan, net buying 110.74 million yuan [2] - San Chuan Wisdom closed up 15.27% with a turnover rate of 32.50%, net buying 75.27 million yuan, but had a net outflow of 35.2 million yuan [2] - Zhongke Magnetic Industry closed down 5.10% with a turnover rate of 45.77%, net buying 53.99 million yuan, but had a net outflow of 49.77 million yuan [2] Market Performance - The average increase of stocks with institutional net purchases was 2.36%, outperforming the Shanghai Composite Index [3] - Stocks like Changrong Co. and Xinling Electric showed strong performance, closing at the daily limit [3] - Historical data indicates a 52.06% probability of stocks with institutional net purchases rising the next day, and a 39.70% probability of rising in the following three days [3] Earnings Forecasts - Among the stocks with institutional net purchases, four have released half-year earnings forecasts, with Yuhua Development expected to have a net profit of 200 million yuan, a year-on-year increase of 708% [3] Net Selling Summary - The stock with the highest net selling by institutions was Siyuan Electric, with a net selling amount of 162.84 million yuan, while also seeing a net inflow of 98.77 million yuan [3] - Dazhihui was noted for a net selling of 120.24 million yuan, with a significant net outflow of 433 million yuan [4] Deep and Shanghai Stock Connect - On July 14, 15 stocks on the trading list had appearances from the Deep and Shanghai Stock Connect, with Siyuan Electric and Zhongke Jincai seeing net purchases of 139 million yuan and 113 million yuan respectively [7][8] - Stocks like Hengbao Co. and Greenland Holdings experienced significant net selling amounts of 193 million yuan and 79.38 million yuan respectively [8]